Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Caffeine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| All patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Caffeine | DRUG | - |
| Warfarin | DRUG | - |
| Omeprazole | DRUG | - |
| Metoprolol | DRUG | - |
| Midazolam | DRUG | - |
| Risankizumab | DRUG | - |
Inclusion criteria: * Signed and dated written informed consent in accordance with GCP (Good Clinical Practice) and local legislation prior to admission to the trial and prior to any trial related procedure. * Age 18 years to 75 years at screening * Body mass index of 18.5 to 40.0 kg/m2 and within ...
Caffeine is an investigational small molecule being studied for use in psoriasis. It is currently in Phase 1 clinical development. The drug is being evaluated for its potential effects in patients with psoriasis, with or without psoriatic arthritis.
Caffeine is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research to evaluate the drug's safety and effects in patients with psoriasis.
Caffeine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial has been completed.
Caffeine has been studied in one clinical trial, identified as NCT02772601. This Phase 1 study tested the effect of risankizumab on the metabolism of five additional drugs, including caffeine, in patients with psoriasis. The trial was completed in Germany with 21 participants.
No, Caffeine is not the same as risankizumab. In clinical trial NCT02772601, caffeine was used as a probe drug to study how risankizumab affects the metabolism of other drugs. Caffeine itself is being investigated as a potential treatment for psoriasis.